Date Announced: Join us on October 17, 2024 in New York City for The Michael J. Fox Foundation's 16th annual Parkinson's Disease Therapeutics Conference. Join over 300 research and business development professionals from both academia and industry for the world's only conference exclusively focused on Parkinson's disease drug development. Use promo code EB2024 for an early bird special (ends July 19). Learn more and register today: https://bit.ly/3x6WUE5
The Michael J. Fox Foundation for Parkinson's Research’s Post
More Relevant Posts
-
On 15 Nov, join the webinar “Where do biosimilars fit into the Cancer treatment puzzle?” to get an overview of the benefits that #BiosimilarMedicines can provide to #CancerCare and join #GlobalBiosimilarsWeek #GBW23 🧪
Global Biosimilars Week 2023
https://www.globalbiosimilarsweek.org/2023
To view or add a comment, sign in
-
Don't forget to join Vigeo Therapeutics COO Dr. Jing Watnick updating the Fifth Annual Glioblastoma Drug Development Summit TODAY at 1:30 PM EDT today (March 28) in Boston, MA. Dr. Watnick will give an overview of #VT1021 in our Ph1/2 program in GBM as well as the future use of #VT1021 in attacking the roots of Neuro-inflammatory disease #GBM #Glioblastoma #NeurodegenerativeDisease #NeuroInflammatoryDisease #GBMSummit
To view or add a comment, sign in
-
[Clinical Trials] Vicore Pharma AB's phase 2a trial of Digital therapy Almee shows a 2.7-point improvement in anxiety symptoms in Anxiety with Pulmonary Fibrosis https://lnkd.in/gY3DpKM3 Soligenix, Inc.'s phase 2a trial of SGX302 demonstrates positive outcomes in treating psoriasis https://lnkd.in/g5S5ce7i Theravance Biopharma US, Inc.'s phase 4 study of YUPELRI reveals no significant difference from Spiriva HandiHaler in COPD https://lnkd.in/gbe-e-6a Jiangsu Simcere Pharmaceutical's phase 3 trial of BD0801 met primary endpoint in ovarian cancer, fallopian tube cancer, and peritoneal cancer patients https://lnkd.in/gRcDwvt5 Stayble Therapeutics' phase 2b trial of STA363 for chronic disc-related back pain did not achieve primary objective https://lnkd.in/g9jTpNY7
Vicore Pharma AB's phase 2a trial of Digital therapy Almee shows a 2.7-point improvement in anxiety symptoms in Anxiety with Pulmonary Fibrosis
efortless.bio
To view or add a comment, sign in
-
********EARLY BIRD ALERT*********** It is early bird week for the 4th B&T Cell Mediated Autoimmune Disease Drug Development Summit! Looking achieve more targeted B cell modulation and depletion in autoimmunity? Attend the 4th B&T Cell Mediated Autoimmune Disease Drug Development to distinguish pathogenic B cells, move beyond lineage depleting strategies, overcome tissue specific delivery challenges and achieve broader efficacy in wider autoimmune patient populations. Join the likes of Namita Gandhi, Andreas Radbruch, Shawn Rose MD, PhD, Carrie Saulsbery, Michael Howell, Kira Rubtsova, Taylor L. Reynolds, Navin Rao, Ph.D., Mark Selby, Jim Paulson, David Rothstein, Sheng Xiao to help bring more targeted tissue and antigen specific therapies to patients in need. This is your last chance to register and take advantage of our largest discounts which end this Friday, September 15. Click here to learn more information: https://ter.li/ot42ia #drugdevelopment #drugdiscovery #autoimmunity
Home – 4th B & T Cell-Mediated Autoimmune Disease Drug Development | Boston, MA
b-and-t-cell-for-autoimmune.com
To view or add a comment, sign in
-
📢𝗖𝗮𝗹𝗹𝗶𝗻𝗴 𝗮𝗹𝗹 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘀𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁𝘀📢…. Are you really going to miss out? UCB & argenx are revolutionizing the field of Fc therapeutics, with their 𝘙𝘰𝘻𝘢𝘯𝘰𝘭𝘪𝘹𝘪𝘻𝘶𝘮𝘢𝘣 and 𝘌𝘧𝘨𝘢𝘳𝘵𝘪𝘨𝘪𝘮𝘰𝘥 FcRn inhibitors, setting new standards in autoimmune disease treatments. Given these breakthroughs, there's no better time to attend the 𝟰𝘁𝗵 𝗙𝗰-𝗠𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻 𝗦𝘂𝗺𝗺𝗶𝘁. Join 𝟲𝟬+ 𝗸𝗲𝘆 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻-𝗺𝗮𝗸𝗲𝗿𝘀 from giants like Sanofi, Genmab, UCB, argenx, and more to uncover groundbreaking insights in targeting FcRn, FcyR, and novel Fc optimization to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘆𝗼𝘂𝗿 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲𝘀 and 𝘀𝘁𝗮𝘆 𝗮𝗵𝗲𝗮𝗱 𝗼𝗳 𝘁𝗵𝗲 𝗰𝘂𝗿𝘃𝗲. Access the full agenda here - https://ter.li/vgaypn Now in its 4th year, this event guarantees 𝘂𝗻𝗽𝗮𝗿𝗮𝗹𝗹𝗲𝗹𝗲𝗱 𝗻𝗲𝘁𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 alongside𝗶𝗻𝘃𝗮𝗹𝘂𝗮𝗯𝗹𝗲 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗮𝗰𝗿𝗼𝘀𝘀 𝟯 𝗷𝗮𝗺-𝗽𝗮𝗰𝗸𝗲𝗱 𝗱𝗮𝘆𝘀 of seminars.💡 Reserve your spot now - https://ter.li/uf4iza and 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 $𝟱𝟬𝟬 𝗯𝗲𝗳𝗼𝗿𝗲 𝗙𝗿𝗶𝗱𝗮𝘆'𝘀 𝗱𝗲𝗮𝗱𝗹𝗶𝗻𝗲. See you at the #𝗙𝗰𝗠𝗲𝗱𝗶𝗮𝘁𝗲𝗱𝗙𝘂𝗻𝗰𝘁𝗶𝗼𝗻𝗦𝘂𝗺𝗺𝗶𝘁 in April, where we'll shape the future of autoimmune disease treatments!
To view or add a comment, sign in
-
-
On May 15th we announced a partnership with Enable Injections to develop a combination product to treat advanced Parkinson's disease. Our chemistry team at Serina spent four years trying to solve the challenges of programming the release of apomorphine from our proprietary POZ polymer. We solved it. We are relentless. SER-252 is a potential breakthrough therapy for advanced disease. We anticipate entering clinical studies in 2025 with a twice per week subcutaneous injection of apomorphine that has the potential to reduce “OFF” time, with no adverse skin reactions and no need for a doctor or nurse to administer it. SER-252 is a preventive therapy (not a rescue therapy) with the potential to increase “ON” time, prevent dyskinesia, and may allow some patients to titrate off all L-DOPA. Leveraging our partnership with Enable Injections, SER-252 is being developed using enFuse®, the innovative wearable drug delivery platform from Enable that allows patient self-administration with rapid treatment time. Go to www.enableinjections.com and www.serinatherapeutics.com to learn more.
Exciting News: Today, Enable announced a new collaboration with Serina Therapeutics, Inc. to develop a potential enFuse® combination product for advanced Parkinson’s disease. Learn more about how Serina’s investigational apomorphine therapy, in combination with enFuse, has the potential to significantly reduce many of the burdens associated with the current standard of care for Parkinson’s patients. https://bit.ly/3WLyCtB
To view or add a comment, sign in
-
-
This is a great example of immunophenotyping on clinical trials. This is from Candel Therapeutics's June 2024 presentation (https://lnkd.in/g9DmSu2i), parts of which were shown at ASCO this weekend. For the uninitiated, in the first slide, you can see the injections generate an immune response at the right times. In the second slide, using multi-parameter cytometry, you can see the detail. The second slide compares changes in immune cells between the first and second CAN-2409 injections in patients who survived less than 24 months versus those who survived 24 months or more. Using multi-parameter cytometry, you can see that patients with a stronger immune activation after the second injection (the top right quadrant) tended to live longer.
To view or add a comment, sign in
-
🙌 Exciting news for liver disease, as Gilead Sciences acquires CymaBay Therapeutics! The acquisition gives Gilead ownership of Seladelpar, a drug to treat Primary Biliary Cholangitis (PBC), a disease which affects the bile ducts that run through the liver. The therapy is currently under review by the FDA, following a recent Phase III RESPONSE trial, which showed statistically significant results versus a placebo. As a fellow therapy developer in the liver disease space, this news is heartening – demonstrating that persistence, adaptability, and focused execution are key to advancing novel medicines for patients. Read more about the acquisition at STAT ⬇️ #biotech #genomics #LiverDisease
Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease
https://www.statnews.com
To view or add a comment, sign in
-
Eli Lilly and Company's Phase III Admirable trial provided positive data for using lebrikizumab, a monoclonal antibody, in individuals with eczema with darker skin tones. The study collected most of its data from people who identified as Black or African American at 80%. Although, 22% of Latinos/Hispanics and 14% of Asian individuals were also part of the trial! The antibody was given to 50 participants for 16 weeks and results showed improvement in 75% of patients of about 68% in severity clearing. Almost 40% of the individuals were able to obtain clear skin with the treatment! A beneficial treatment and development for eczema patients! Learn more at the link! https://hubs.li/Q02nZNc00
Lilly’s eczema drug shows improvement in people with darker skin tones
To view or add a comment, sign in
-
We are proud to present you with the innovations in parenteral delivery in this issue of The Formula. You will learn how a solid foundation of skilled professionals and quality systems derisks parenteral drug manufacturing. And, hear from the secrets from a renowned scientist for problem solving parenteral drug formulations. Finally, you will gain exclusive insight about advancements in targeted parenteral delivery for treating cancer. https://hubs.ly/Q02l0KVb0 #pii #cdmo #parenteral
To view or add a comment, sign in
-